Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

Recruiting

I'm Interested

Trial ID: NCT02250651

Age - 18 Years-N/A Gender - All Accepting Healthy Volunteers - No

Purpose

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Official Title

The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension

Stanford Investigator(s)

Ann Caroline Fisher, MD
Ann Caroline Fisher, MD

Clinical Associate Professor, Ophthalmology

Eligibility


Inclusion Criteria:

- Diagnosis of either open-angle glaucoma or ocular hypertension in each eye and both eyes
require IOP-lowering treatment.

Exclusion Criteria:

   - Previous enrollment in another Allergan Bimatoprost SR Study

   - Eye surgery (including cataract surgery) and/or any eye laser surgery within the past
   6 months in the study eye

   - Anticipated need for laser eye surgery within the first 52 weeks of the study duration

   - History of glaucoma surgery

View More
View Less

Intervention(s):

drug: Timolol Vehicle (placebo)

drug: Bimatoprost SR

other: Sham: Applicator Without Needle

drug: Active Comparator: Timolol 0.5%

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mariana Nunez
650-724-3734

©2024 Stanford Medicine